Marketdash
Back to News

Three Oversold Healthcare Stocks Worth Watching This December

MarketDash Editorial Team
5 days ago
When healthcare stocks get beaten down to oversold territory, it can signal a buying opportunity for investors willing to dig into the fundamentals. Three companies have recently hit RSI levels below 30, suggesting they might be due for a bounce after taking some serious hits.

When stocks get hammered hard enough, they eventually enter what technical analysts call "oversold" territory. It's not a guarantee of a rebound, but it often means the selling has gotten a bit excessive relative to the company's actual prospects. In the healthcare sector right now, three stocks have hit that point, with Relative Strength Index (RSI) readings hovering near or below 30.

The RSI is basically a momentum gauge that compares how strong a stock is on up days versus down days. Think of it as a sentiment meter. When the RSI drops below 30, it suggests that selling pressure may have gotten overdone, and the stock could be primed for a reversal. At the very least, it's worth a closer look to see if the market is overreacting to bad news or if there's genuine trouble brewing.

Here are three healthcare names that have been taking a beating lately but might be setting up for a December comeback.

Larimar Therapeutics: Down But Not Out

Larimar Therapeutics Inc. (LRMR) has had a rough go of it recently. The stock has dropped about 20% over the past month and now sits near its 52-week low of $1.61. The company posted a wider-than-expected quarterly loss on November 5, which didn't help matters. But here's where it gets interesting: the clinical data for their Friedreich's ataxia treatment is actually looking pretty encouraging.

"We were pleased to recently share exciting long-term data from our open label study showing consistent directional improvement across four key clinical outcome measures relative to a Friedrich's Ataxia Clinical Outcomes Measure Study (FACOMS) reference population, and increased skin frataxin (FXN) levels similar to asymptomatic carriers," said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar. "These findings underscore the potential of daily nomlabofusp treatment to help change the disease course of patients living with Friedreich's ataxia (FA), including those with advanced disease."

The disconnect between promising clinical progress and a tanking stock price is exactly the kind of situation that can create opportunities. The current RSI sits at 29.9, firmly in oversold territory. Shares closed at $3.12 on Tuesday, down 12.1%. The Edge Stock Ratings show a momentum score of 23.98.

Perrigo Company: Market Share Gains Amid Headwinds

Perrigo Company PLC (PRGO) has been absolutely crushed, falling roughly 34% over the past month and trading near its 52-week low of $12.17. The company reported mixed third-quarter results on November 5 and slashed its fiscal 2025 adjusted EPS guidance below analyst expectations. That's the kind of news that sends investors running for the exits.

But dig a little deeper, and the picture gets more nuanced. Despite the challenging environment, Perrigo is actually gaining market share in several key categories. President and CEO Patrick Lockwood-Taylor explained: "While OTC consumption was increasingly soft in the third quarter, the Perrigo team delivered strong in-market performance. We gained dollar, unit and volume share in five of seven store brand categories and grew share in our key brands, a clear sign that consumers are choosing Perrigo products at the shelf. This performance, despite a challenging backdrop, reflects the strength of our Three-S plan (Stabilize, Streamline, Strengthen) and our commitment to delivering trusted, accessible health solutions across multiple price points."

In other words, consumers are still picking Perrigo products even when overall demand is soft. That's the kind of competitive strength that can pay off when market conditions improve. The RSI currently stands at 29.9, matching Larimar's oversold reading. Shares fell 1.7% to close at $13.61 on Tuesday.

ORIC Pharmaceuticals: Analyst Optimism Despite Recent Weakness

ORIC Pharmaceuticals Inc. (ORIC) rounds out the trio with a decline of approximately 16% over the past month, bringing it near its 52-week low of $3.90. Unlike the other two companies, ORIC didn't suffer from disappointing earnings. Instead, the stock has been caught up in broader market weakness.

What's particularly interesting here is the timing. On November 20, Evercore ISI Group initiated coverage on the stock with an Outperform rating and set a $25 price target. That's more than double where the stock is currently trading. When a major analyst firm comes out bullish right as a stock hits oversold levels, it's worth paying attention.

The RSI for ORIC sits at 29.6, the lowest of the three stocks on this list. Shares dropped 4.5% to close at $10.65 on Tuesday. If Evercore's price target has any merit, there's substantial upside potential from current levels.

The Bottom Line on Oversold Opportunities

It's important to remember that oversold doesn't automatically mean "buy." A stock can always get more oversold, and sometimes the market is selling off for very good reasons. But when you see companies with solid fundamentals, encouraging clinical data, or strong analyst support trading at technically oversold levels, it's at least worth investigating whether the market has overreacted.

All three of these healthcare stocks have been beaten down significantly over the past month. Whether they bounce back in December depends on a lot of factors beyond just technical indicators. But for investors looking for potential value plays in the healthcare sector, these oversold names offer an interesting starting point for further research.

Back to News

Three Oversold Healthcare Stocks Worth Watching This December

MarketDash Editorial Team
5 days ago
When healthcare stocks get beaten down to oversold territory, it can signal a buying opportunity for investors willing to dig into the fundamentals. Three companies have recently hit RSI levels below 30, suggesting they might be due for a bounce after taking some serious hits.

When stocks get hammered hard enough, they eventually enter what technical analysts call "oversold" territory. It's not a guarantee of a rebound, but it often means the selling has gotten a bit excessive relative to the company's actual prospects. In the healthcare sector right now, three stocks have hit that point, with Relative Strength Index (RSI) readings hovering near or below 30.

The RSI is basically a momentum gauge that compares how strong a stock is on up days versus down days. Think of it as a sentiment meter. When the RSI drops below 30, it suggests that selling pressure may have gotten overdone, and the stock could be primed for a reversal. At the very least, it's worth a closer look to see if the market is overreacting to bad news or if there's genuine trouble brewing.

Here are three healthcare names that have been taking a beating lately but might be setting up for a December comeback.

Larimar Therapeutics: Down But Not Out

Larimar Therapeutics Inc. (LRMR) has had a rough go of it recently. The stock has dropped about 20% over the past month and now sits near its 52-week low of $1.61. The company posted a wider-than-expected quarterly loss on November 5, which didn't help matters. But here's where it gets interesting: the clinical data for their Friedreich's ataxia treatment is actually looking pretty encouraging.

"We were pleased to recently share exciting long-term data from our open label study showing consistent directional improvement across four key clinical outcome measures relative to a Friedrich's Ataxia Clinical Outcomes Measure Study (FACOMS) reference population, and increased skin frataxin (FXN) levels similar to asymptomatic carriers," said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar. "These findings underscore the potential of daily nomlabofusp treatment to help change the disease course of patients living with Friedreich's ataxia (FA), including those with advanced disease."

The disconnect between promising clinical progress and a tanking stock price is exactly the kind of situation that can create opportunities. The current RSI sits at 29.9, firmly in oversold territory. Shares closed at $3.12 on Tuesday, down 12.1%. The Edge Stock Ratings show a momentum score of 23.98.

Perrigo Company: Market Share Gains Amid Headwinds

Perrigo Company PLC (PRGO) has been absolutely crushed, falling roughly 34% over the past month and trading near its 52-week low of $12.17. The company reported mixed third-quarter results on November 5 and slashed its fiscal 2025 adjusted EPS guidance below analyst expectations. That's the kind of news that sends investors running for the exits.

But dig a little deeper, and the picture gets more nuanced. Despite the challenging environment, Perrigo is actually gaining market share in several key categories. President and CEO Patrick Lockwood-Taylor explained: "While OTC consumption was increasingly soft in the third quarter, the Perrigo team delivered strong in-market performance. We gained dollar, unit and volume share in five of seven store brand categories and grew share in our key brands, a clear sign that consumers are choosing Perrigo products at the shelf. This performance, despite a challenging backdrop, reflects the strength of our Three-S plan (Stabilize, Streamline, Strengthen) and our commitment to delivering trusted, accessible health solutions across multiple price points."

In other words, consumers are still picking Perrigo products even when overall demand is soft. That's the kind of competitive strength that can pay off when market conditions improve. The RSI currently stands at 29.9, matching Larimar's oversold reading. Shares fell 1.7% to close at $13.61 on Tuesday.

ORIC Pharmaceuticals: Analyst Optimism Despite Recent Weakness

ORIC Pharmaceuticals Inc. (ORIC) rounds out the trio with a decline of approximately 16% over the past month, bringing it near its 52-week low of $3.90. Unlike the other two companies, ORIC didn't suffer from disappointing earnings. Instead, the stock has been caught up in broader market weakness.

What's particularly interesting here is the timing. On November 20, Evercore ISI Group initiated coverage on the stock with an Outperform rating and set a $25 price target. That's more than double where the stock is currently trading. When a major analyst firm comes out bullish right as a stock hits oversold levels, it's worth paying attention.

The RSI for ORIC sits at 29.6, the lowest of the three stocks on this list. Shares dropped 4.5% to close at $10.65 on Tuesday. If Evercore's price target has any merit, there's substantial upside potential from current levels.

The Bottom Line on Oversold Opportunities

It's important to remember that oversold doesn't automatically mean "buy." A stock can always get more oversold, and sometimes the market is selling off for very good reasons. But when you see companies with solid fundamentals, encouraging clinical data, or strong analyst support trading at technically oversold levels, it's at least worth investigating whether the market has overreacted.

All three of these healthcare stocks have been beaten down significantly over the past month. Whether they bounce back in December depends on a lot of factors beyond just technical indicators. But for investors looking for potential value plays in the healthcare sector, these oversold names offer an interesting starting point for further research.

    Three Oversold Healthcare Stocks Worth Watching This December - MarketDash News